Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science and the strategy inside Quantum BioPharma disclosures can feel like decoding two companies at once. The 200-page annual report details proprietary myelin-repair research while dozens of 8-K updates flag shifts in its real-estate-backed investment arm. If you’ve ever asked, “What does Quantum BioPharma report in their SEC filings?” or hunted for a single trial milestone among footnotes, you know the challenge.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI that translates every section into plain English. Whether you need the Quantum BioPharma quarterly earnings report 10-Q filing or want Quantum BioPharma Form 4 insider transactions real-time, our dashboard highlights the numbers that move the stock. Key documents are linked with short, shareable summaries so Quantum BioPharma SEC filings explained simply stay accurate. You’ll see at a glance how cash from strategic investments funds Phase-2 trials, what the latest Quantum BioPharma 8-K material events explained mean for risk, and how R&D spending trends quarter over quarter.
- AI-powered summaries of 10-K, 10-Q, and 8-K
- Real-time Quantum BioPharma insider trading Form 4 transactions alerts
- Side-by-side financial and R&D trend analysis
- Instant download of all exhibits and XBRL data
Still digging deeper? Activate comparison tools for Quantum BioPharma annual report 10-K simplified, generate a Quantum BioPharma earnings report filing analysis, or set alerts for Quantum BioPharma executive stock transactions Form 4. We also surface voting matters in the Quantum BioPharma proxy statement executive compensation so institutions can model dilution before it happens. By understanding Quantum BioPharma SEC documents with AI, analysts monitor pipeline progress, insider sentiment, and capital allocation—without wading through legalese.
Quantum BioPharma Ltd. furnished a Form 6-K announcing it entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC to permit sales of its Class B Subordinate Voting Shares. A Canadian counsel legal opinion on the validity of the shares and the ATM agreement are attached as exhibits and incorporated by reference into the company’s Form F-3 (File No. 333-276264).
Quantum BioPharma Ltd. (QNTM) launched a primary at-the-market (ATM) offering of up to US$21,225,000 of Class B Subordinate Voting Shares under a Sales Agreement with H.C. Wainwright & Co., acting as sales agent or principal. Sales may be made from time to time on Nasdaq or through other permitted methods, after the company delivers sales notices.
The company will pay a 3.0% commission on gross proceeds to the sales agent and intends to use any net proceeds for working capital and general corporate purposes. No sales will be made in Canada or over the facilities of the CSE or other Canadian markets. The shares trade as “QNTM” on Nasdaq and the CSE, and “0K91” on Frankfurt.
As disclosed for Form F‑3 eligibility, the company’s public float was approximately US$67,723,261, and, after US$1,326,147 sold in the prior 12 months, it states capacity to sell up to US$21,248,272 under General Instruction I.B.5 so long as the float remains below US$75.0 million. The filing highlights risks typical of ATM programs, including potential dilution, price variability during sales, reliance on management’s broad use of proceeds discretion, PFIC tax considerations for U.S. holders, Nasdaq listing compliance risk, and volatility tied to its cryptocurrency treasury investments.
Quantum Biopharma Ltd. filed an amended Form 6‑K to correct an exhibit previously furnished. The company states that an incorrect version of Exhibit 99.1 accompanied its April 16, 2024 submission, and this amendment is furnished solely to provide the correct exhibit.
The amendment does not modify or update other disclosures from the original report. The corrected Exhibit 99.1 is titled “Press Release dated April 1, 2024 - FSD Pharma Announces Filing of Year-End 2023 Results.”
Quantum Biopharma Ltd. filed an amended Form 6-K to correct an administrative error in the exhibit index of a prior submission. The amendment updates the description of Exhibit 99.1 only and states it does not modify or update any other disclosures from the original report.
Exhibit 99.1 is identified as a press release dated January 29, 2024 regarding FSD Pharma board changes and corporate updates. The filing was executed on behalf of the company by Chief Financial Officer Donal Carroll.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
